<DOC>
	<DOC>NCT01514227</DOC>
	<brief_summary>NIPPON trial is a prospective, randomized, trial comparing 6 and 18 months Dual Antiplatelet Therapy (DAPT) following Nobori stent deployment.</brief_summary>
	<brief_title>Nobori Dual Antiplatelet Therapy as Appropriate Duration</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Subjects &gt; 20 years old Undergoing percutaneous intervention with Nobori deployment No contraindication to prolonged DAPT Subjects absolutely necessitating continuous DAPT Planned surgery necessitating discontinuation of antiplatelet therapy after enrollment. Active pathological bleeding Status of cardiogenic shock at enrollment Pregnant women Life expectancy of &lt; 1.5 years Subjects unable to give informed consent Episode of stroke &lt; 6 months Subjects with allergies or hypersensitivity to material of coating, Biolimus A9, and antiplatelet drugs. Subjects treated with other kind of DES or BMS during the index procedure Previous intervention with DES &lt; 6 months. Study participation impractical per investigator judgment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>